*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.
GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.
Researchers from Lifeline Cell Technology, a subsidiary of International Stem Cell Corp., and the Scientific Center for Obstetrics, Gynecology, and Perinatology RAMS in Moscow recently reported a major advance in human stem cell research. They produced patient-specific parthenogenetic stem cells using unfertilized human eggs that are pluripotent and functionally comparable to embryonic stem cells and are genetically matched to the female donor's immune system. The report provides a documented protocol that can be used to derive stem cell lines from human parthenogenetic embryos, according to the scientists, who add that the method minimizes the presence of animal-derived components, making the stem cells more suitable for clinical use in humans.
The paper has been published online ahead of print in Cloning and Stem Cells, a peer-reviewed journal published by Mary Ann Liebert, Inc., and is available free online at /www.liebertpub.com/clo..
During this week's podcast, Jeff Krstich and Jeffrey Janus, both from International Stem Cell Corp., talk about the broad implications and significance of this accomplishment. They provide specific details of the experiment and discuss how they demonstrated that the parthenogenetic stem cells were similar to and functioned like embryonic stem cells derived from fertilized embryos.
Krstich and Janus also list the clinical applications that would be most appropriate for applications of this new technology and suggest protocols that might enable these cells to become therapies for someone other than the egg donor. They also explain why they believe this approach avoids the ethical issues raised by opponents of embryonic stem cell therapy.
Listen to this important podcast then return to the blog to answer the following question:
Do you believe this approach to deriving human stem lines is promising and, if so, why? Do you see any problems with this research technique?
Or, if you prefer, post your own topic on the biotech industry subject of your choice. Please share your opinions and observations.
Jeffrey Janus is President of International Stem Cell Corporation (ISCO.OB) and founder of ISC subsidiary Lifeline Cell Technology. He has over 18 years experience creating profitable commercial cell based businesses. Prior to Lifeline, Mr. Janus led in the development and commercialization of Clonetics Corporation and the Clonetics brand of human cell products for both research and clinical use. That company was successfully sold in 1995 after ten consecutive years of profitable growth exceeding 20%. Mr. Janus has organized businesses providing unique research products using living cells to conduct drug screening in the pharmaceutical industry, product testing in the consumer products industry and basic research at Universities and Government laboratories. Mr. Janus has a MBA and a Bachelor's degree in Biochemistry. E-Mail: [email protected]
Jeff Krstich is CEO of International Stem Cell Corporation (ISCO.OB). He has over 28 years of experience in Biotech, Diagnostics, and Medical Device companies. Prior to ISC, he was involved in the recapitalization and sale of Pathology Partners Inc. to CARIS Ltd, and prior to that was President of MarketStar HealthCare a subsidiary of Omnicom (NYSE-OMC). As Director of Sales at Biogen (NASDQ-BIIB) he was instrumental in creating their fully integrated organization and growing revenues to over $600 million in four years. Earlier he was with Baxter Healthcare (NYSE-BAX), and American Hospital Supply. A former Navy Test Pilot and veteran of Vietnam and Gulf Storm, he has an MBA and BS from the United States Naval Academy. E-Mail: [email protected]